Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Phospholipase A2 Inhibitor
Ro 31-4639 is a potent inhibitor of phospholipase A2, displaying an IC50 of 1.5 μM. This compound is valuable for studying the role of phospholipase A2 in inflammatory processes and membrane biochemistry. Its inhibitory activity makes it a critical tool in investigating pathways related to lipid metabolism and the modulation of arachidonic acid release. -
cPLA2 Inhibitor
AK106-001616 is a selective inhibitor of cytosolic phospholipase A2 (cPLA2), exhibiting a potent inhibition with an IC50 of 3.8 nmol/L. This compound effectively reduces the synthesis of pro-inflammatory mediators, including prostaglandins E2 and leukotrienes B4, in stimulated cells. AK106-001616 is valuable for research into inflammatory diseases, neuropathic pain, and pulmonary fibrosis, providing insights into the modulation of inflammatory pathways. -
Phospholipase C Inhibitor
Hispidospermidin is a selective inhibitor of phospholipase C, a key enzyme involved in various signal transduction pathways. This compound exhibits significant biological activity by modulating intracellular calcium signaling and inositol phosphate metabolism. Its potential applications in research include studying cellular signaling mechanisms and investigating diseases related to dysregulated phospholipase C activity. -
ASM Inhibitor
ARC39 is a selective inhibitor of acid sphingomyelinase (ASM), a key enzyme involved in sphingolipid metabolism. By inhibiting ASM, ARC39 modulates sphingolipid levels, which play critical roles in cellular signaling and stress responses. Its biological activity makes it a valuable tool for research related to neurodegenerative diseases, cancer, and inflammation, facilitating the exploration of sphingolipid-related pathways in various cellular contexts. -
N-SMase 2 Inhibitor
DPTIP hydrochloride is a selective inhibitor of neutral sphingomyelinase 2 (N-SMase 2), exhibiting an IC50 of 30 nM. This compound is known for its ability to penetrate the blood-brain barrier, making it a valuable tool for studying exosome-mediated cellular processes. Research applications include investigations into neurodegenerative diseases and the role of sphingosine metabolism in cellular signaling pathways. -
nSMase Inhibitor
Sphingolactone-24 is a selective and irreversible inhibitor of neutral sphingomyelinase (nSMase). This compound is significant in biological research due to its ability to modulate sphingolipid metabolism, which plays a critical role in various cellular processes. Sphingolactone-24 is particularly useful in studies related to acute lung injury, enabling researchers to explore therapeutic interventions in respiratory conditions associated with nSMase activity. -
Group IVA Cytosolic Phospholipase A2 Inhibitor
GK470 is a potent inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. This compound exhibits significant anti-inflammatory activity by inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes, with an IC50 of 0.6 μM. GK470 demonstrates comparable anti-inflammatory effects to conventional therapies in models of arthritis and effectively reduces plasma PGE2 levels, making it a valuable tool for researching inflammatory pathways and potential therapeutic interventions. -
PYK Inhibitor
NCGC00188636 is a novel covalent inhibitor of pyruvate kinase (PYK). By blocking nucleotide binding at the active site, NCGC00188636 disrupts PYK activity, thereby influencing metabolic processes. This compound is suited for research into the metabolic pathways of various organisms and cell types, providing insights into cellular energy regulation and potential therapeutic targets. -
AR Degrader/CYP17A1 Inhibitor
YXG-158 is an orally active androgen receptor (AR) degrader and CYP17A1 inhibitor. It exhibits AR degradation activity with a DC50 value of 1.28 μM and inhibits CYP17A1 with an IC50 value of 100 nM. This compound is particularly relevant for research applications focused on enzalutamide-resistant prostate cancer, providing a valuable tool for investigating therapeutic strategies in this context. -
MAO-B Inhibitor
MAO-B-IN-10 is a selective monoamine oxidase B (MAO-B) inhibitor with a potent IC50 of 5.3 μM. It effectively inhibits and disaggregates amyloid β (Aβ) aggregation, achieving 58.2% inhibition and 43.3% disaggregation of self-mediated Aβ. This compound is valuable for research related to Alzheimer's disease, offering insights into the modulation of Aβ aggregation in neurodegenerative processes. -
MAO-B Inhibitor
MAO-B-IN-50 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.06 μM. This compound is effective in inhibiting the aggregation of amyloid-beta (Aβ40/42) and Tau proteins, with overall IC50 values near 1 μM. Additionally, MAO-B-IN-50 shows potent selective inhibition of acetylcholinesterase (AChE) with an IC50 of 1.78 μM. It is suitable for use in research related to Alzheimer's disease. -
AChE/MAO-B Inhibitor
AChE/MAO-B-IN-9 is a selective, reversible, non-competitive inhibitor of acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B), exhibiting an IC50 of 0.156 μM against electric eel AChE. This compound effectively inhibits the formation of Aβ40/42 fibrils, promotes the depolymerization of Aβ fibrils, and suppresses Tau protein fibril formation. Additionally, AChE/MAO-B-IN-9 demonstrates antioxidant and neuroprotective properties, while alleviating memory deficits induced by scopolamine in murine models. This reagent is valuable for research related to Alzheimer’s disease. -
BuChE inhibitor
Iso-OMPA (Tetraisopropyl pyrophosphoramide) is a selective inhibitor of butyrylcholinesterase (BuChE), functioning through irreversible inhibition. This compound is primarily utilized in research to investigate the mechanisms of BuChE and the resulting effects on acetylcholine metabolism. Iso-OMPA has been shown to enhance soman toxicity in rat models, linked to the inhibition of plasma carboxylesterase (CarbE), making it a valuable tool in studies of nerve agent effects and cholinergic signaling. -
CYP2D6/AChE Inhibitor
Rhodiosin is a dual inhibitor of CYP2D6 and acetylcholinesterase (AChE), extracted from the root of Rhodiola rosea. It exhibits an IC50 value of 0.761 μM for CYP2D6 and a Ki of 0.769 μM. This compound demonstrates notable antioxidant and neuroprotective properties, contributing to the regulation of the HIF-1α signaling pathway, which is vital for central nervous system protection. Rhodiosin serves as a valuable tool for research in neuropharmacology and metabolic studies. -
Dual MAO/AChE Inhibitor
Ladostigil hemitartrate is a dual inhibitor of monoamine oxidase (MAO) and acetylcholinesterase (AChE), with established IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. This compound is capable of crossing the blood-brain barrier and exhibits neuroprotective, antioxidant, and anti-inflammatory properties. Ladostigil hemitartrate is relevant for research into neurological disorders, including depression and Alzheimer's disease. Additionally, it functions as a click chemistry reagent, featuring an alkyne group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
MAO/AChE Inhibitor
Ladostigil hydrochloride is a potent dual inhibitor of acetylcholinesterase (AChE) and monoamine oxidase-B (MAO-B), exhibiting IC50 values of 37.1 µM and 31.8 µM, respectively. This compound demonstrates neuroprotective, antioxidant, and anti-inflammatory properties, making it valuable for research related to depression and Alzheimer's disease. Additionally, Ladostigil hydrochloride functions as a click chemistry reagent, featuring an alkyne group that can participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating diverse chemical applications. -
Dual MAO and AChE Inhibitor
Ladostigil is a dual inhibitor of monoamine oxidase (MAO) and acetylcholinesterase (AChE), demonstrating IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. This compound exhibits neuroprotective, antioxidant, and anti-inflammatory properties, making it valuable for research in conditions such as depression and Alzheimer's disease. Additionally, Ladostigil features an alkyne functional group, enabling it to serve as a click chemistry reagent through copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
MAO Inhibitor
ASS234 is a potent monoamine oxidase (MAO) inhibitor, targeting MAO-A and MAO-B with IC50 values of 5.2 nM and 43 nM, respectively. In addition to its primary activity, ASS234 also exhibits inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), with IC50 values of 350 nM and 460 nM, respectively. This compound can be utilized in research related to neurodegenerative diseases, mood disorders, and cholinergic signaling pathways. -
AChE-MAO B Inhibitor
Dual AChE-MAO B-IN-2 is a powerful inhibitor of both acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), exhibiting IC50 values of 0.12 µM and 0.01 µM, respectively. This dual inhibition profile suggests its significant potential in the study and development of therapeutic strategies for Alzheimer's disease. Researchers can utilize Dual AChE-MAO B-IN-2 to explore mechanisms related to cholinergic dysfunction and oxidative stress in neurodegenerative conditions. -
ChEs/MAOs Inhibitor
ChEs/MAOs-IN-2 is a potent inhibitor of cholinesterases and monoamine oxidases, exhibiting IC50 values of 0.10 µM for MAO-A, 0.20 µM for MAO-B, 0.30 µM for acetylcholinesterase (AChE), and 0.40 µM for butyrylcholinesterase (BChE). This compound demonstrates significant biological activity relevant to neurodegenerative diseases, particularly Alzheimer's disease, and serves as a valuable tool for research into therapeutic strategies targeting these enzymes. -
ChE/MAO-A Inhibitor
Desoxypeganine is a potent alkaloid that serves as an inhibitor of cholinesterase (both BChE and AChE) as well as a selective inhibitor of monoamine oxidase A (MAO-A), exhibiting IC50 values of 2, 17, and 2 μM, respectively. This compound is primarily utilized in research related to alcohol abuse, offering valuable insights into the underlying mechanisms of addiction and potential therapeutic approaches. Its dual inhibitory action positions Desoxypeganine as a significant tool in the study of neurochemical pathways involved in substance use disorders. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-5 is a multitarget inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B). With IC50 values of 0.24 µM, 6.29 µM, and 0.11 µM for AChE, BChE, and MAO-B, respectively, this compound demonstrates potent inhibition of key enzymes involved in cholinergic neurotransmission and monoamine metabolism. AChE/BChE/MAO-B-IN-5 is particularly relevant for research into neurodegenerative diseases, including Alzheimer's disease, due to its ability to penetrate the blood-brain barrier. -
AChE/BuChE/MAO-B Inhibitor
AChE/BuChE/MAO-B-IN-1 is a potent inhibitor of human acetylcholinesterase (hAChE), butyrylcholinesterase (hBuChE), and monoamine oxidase-B (hMAO-B), with IC50 values of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. This compound also demonstrates a high affinity for σ1 and σ2 receptors, with Ki values of 42.8 nM and 191 nM, respectively. AChE/BuChE/MAO-B-IN-1 is potentially useful in research focused on Alzheimer's disease and related neurological disorders. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-1 is a reversible inhibitor targeting acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B), exhibiting IC50 values of 7.31 μM, 0.56 μM, and 26.1 μM, respectively. This compound effectively crosses the blood-brain barrier and demonstrates neuroprotective properties while maintaining a lack of cytotoxicity. Its multifaceted inhibition profile makes it a valuable tool for research on neurodegenerative diseases and associated pathways. -
Dual MAO-AChE Inhibitor
MAO-A/B-IN-3 is a dual inhibitor targeting both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), as well as acetylcholinesterase (AChE). With IC50 values of 67 nM for MAO-A, 29 nM for MAO-B, and 1370 nM for AChE, this compound demonstrates substantial multi-target efficacy. MAO-A/B-IN-3 modifies key binding sites to enhance its inhibitory activity against MAO enzymes while reducing the impact on AChE. This reagent is particularly relevant for research focused on neurodegenerative disorders. -
AChE Inhibitor
AChE-IN-20 is a potent acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 value of 397.32 nM and a Ki value of 335.76 nM. In addition to its primary target, AChE-IN-20 exhibits significant inhibitory activity against human carbonic anhydrases I and II, and α-glucosidase, with IC50 values of 84.14 nM, 69.24 nM, and 52.08 nM, respectively. This compound is valuable for research into neurodegenerative diseases and enzymatic regulation, providing insights into potential therapeutic strategies. -
MAO Inhibitor
Benzylhydrazine is a potent inhibitor of monoamine oxidase (MAO), targeting both brain and liver tissues. It exhibits significant inhibitory activity with pI50 values of 6.3 and 7.0 for brain and liver MAO, respectively. In vivo studies have demonstrated its efficacy in mice, with effective doses (ED50) of 6.5 μmol/kg for brain MAO and 6.2 μmol/kg for liver MAO. This compound is useful for research involving neurochemistry and metabolic studies related to neurotransmitter regulation. -
MAOA Inhibitor
Ethyl homovanillate is a selective inhibitor of monoamine oxidase A (MAOA) with an IC50 value of 8.1 μM. This compound demonstrates significant efficacy in improving depressive-like behavior, as evidenced by enhanced scores in the forced swim test in ICR mice. Ethyl homovanillate is a valuable reagent for investigating the mechanisms underlying neurological diseases, particularly Alzheimer's disease, and offers potential insights into therapeutic strategies for mood regulation. -
Monoamine Oxidase Inhibitor
Pargyline is an irreversible monoamine oxidase (MAO) inhibitor, displaying Ki values of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. This compound exhibits notable antihypertensive and anticancer activities. Additionally, Pargyline functions as a click chemistry reagent due to its alkyne group, allowing for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. -
MAO-A Inhibitor
Clorgyline is a selective inhibitor of monoamine oxidase A (MAO-A) that is orally active and permeable to the blood-brain barrier. By inhibiting MAO-A, Clorgyline decreases the metabolism of neurotransmitters like serotonin (5-hydroxytryptamine), resulting in increased levels in the brain. This compound is particularly valuable for research applications focused on depression and neurodegenerative diseases. -
MAO-B Inhibitor
Mofegiline hydrochloride is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B), exhibiting a significant preference over monoamine oxidase A (MAO-A) with IC50 values of 3.6 nM and 680 nM, respectively. This compound also inhibits semicarbazide-sensitive amine oxidase (SSAO). Mofegiline hydrochloride is utilized in research focused on neurodegenerative disorders and the modulation of neurotransmitter levels. Its specific action on MAO-B makes it a valuable tool in studies addressing dopamine metabolism and potential therapeutic strategies for Parkinson's disease. -
MAO-B Inhibitor
Tisolagiline is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 8 nM. This compound demonstrates neuroprotective effects and possesses anti-neuroinflammatory properties, making it valuable for research in neurological disorders. Tisolagiline may be useful in studying the role of MAO-B in neurodegenerative conditions and evaluating potential therapeutic strategies for such diseases. -
MAO-B Inhibitor
Methyl citrate is a potent inhibitor of Monoamine oxidase B (MAO-B), exhibiting an IC50 value of 0.23 mM. Isolated from the fruits of Opuntia ficus-indica var. saboten, this compound demonstrates significant biological activity relevant for neuropharmacological research. Methyl citrate may be utilized in studies investigating its potential effects on neurodegenerative diseases associated with dopaminergic dysfunction. -
hMAO-A Inhibitor
Obtusin is a selective and competitive inhibitor of human monoamine oxidase-A (hMAO-A) with an IC50 of 11.12 μM and a Ki of 6.15 μM. Isolated from the seeds of Cassia obtusifolia Linn, Obtusin demonstrates potential neuroprotective effects, making it relevant for research into neurodegenerative diseases, particularly those associated with anxiety and depression. Its ability to inhibit hMAO-A may contribute to the modulation of serotonin and norepinephrine levels, offering a valuable tool for elucidating mechanisms underlying mood disorders. -
MAO-A Inhibitor
MAO-A Inhibitor 1 is a selective inhibitor of monoamine oxidase A (MAO-A), exhibiting an IC50 of 100 μM. This compound is instrumental in research applications focused on neuropsychiatric disorders, where modulation of monoamine levels may offer therapeutic potential. It serves as a valuable tool in studies investigating the effects of MAO-A inhibition on neurotransmitter metabolism and related pathophysiological conditions. -
Monoamine Oxidase Inhibitor
Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A (MAO-A). This compound demonstrates significant activity in modulating neurotransmitter levels by inhibiting the oxidative deamination of monoamines, making it a valuable tool for research in neurochemistry and psychiatric disorders. Eprobemide is utilized in studies exploring depression, anxiety, and other conditions associated with monoamine imbalance. -
MAO-A/MAO-B Inhibitor
(-)-2-Phenylpropylamine is an inhibitor of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), exhibiting Ki values of 584 μM and 156 μM, respectively. This compound is utilized in research investigating neurotransmitter regulation and is of particular interest in studies related to mood disorders and neurodegenerative diseases. Its dual inhibition of MAO isoforms makes it a valuable tool for understanding the biochemical pathways involved in monoamine metabolism. -
MAO-B Inhibitor
(Rac)-Rasagiline functions as a selective inhibitor of monoamine oxidase B (MAO-B). This compound exhibits neuroprotective properties, particularly against MPTP-induced neuronal toxicity, making it a valuable tool in Parkinson's disease research. Its capacity to modulate monoaminergic systems may provide insights into therapeutic strategies for neurodegenerative disorders. -
MAO A Inhibitor
Tetrindole mesylate is a selective inhibitor of monoamine oxidase A (MAO A). It competitively inhibits rat brain mitochondrial MAO A with a Ki value of 0.4 μM, while also exhibiting weaker inhibition of MAO B with a Ki of 110 μM. This compound demonstrates antidepressant activity, making it relevant for research in psychiatric disorders and neuropharmacology. -
MAO A Inhibitor
Esuprone is a selective inhibitor of monoamine oxidase A (MAO A) with an IC50 of 7.3 nM, demonstrating significant brain penetration and oral bioavailability. This compound is valuable for neurological research, contributing to the study of mood disorders and neurodegenerative diseases by modulating neurotransmitter levels. -
MAO Inhibitor
Tetrahydroharmine is a selective monoamine oxidase (MAO) inhibitor with an IC50 value of 74 nM for MAO-A. This compound is of significant interest in the study of neurodegenerative diseases, as it may enhance monoamine neurotransmitter levels and provide neuroprotective effects. Its application in research includes exploring therapeutic strategies for conditions like depression and neurodegeneration. -
MAO-B Inhibitor
Tisolagiline monomethylsulfate is a selective, reversible inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 8 nM. It demonstrates neuroprotective effects and possesses anti-neuroinflammatory properties, making it a valuable compound for researching neurodegenerative diseases and related disorders. This reagent is suitable for studies focused on neuroprotection and inflammation modulation in various cellular and animal models. -
Monoamine Oxidase Inhibitor
Chrysophanol-1-O-β-gentiobioside is an anthraquinone glycoside that selectively inhibits the hMAO-A isozyme, exhibiting an IC50 value of 96.15 μM. This compound is primarily utilized in research focused on the modulation of monoamine oxidase activity, making it relevant for studies on neurological disorders and related pharmacological applications. Its unique structure and biological properties contribute to its potential for advancing therapeutic innovations. -
MAO-A/-B Inhibitor
MAO-IN-M30 dihydrochloride is a selective and irreversible inhibitor of monoamine oxidases A and B, with IC50 values of 37 nM and 57 nM, respectively. This compound demonstrates significant neuroprotective properties, effectively mitigating brain cell apoptosis induced by Dexamethasone. Additionally, it exhibits neurorestorative effects in models of Parkinson's disease, specifically post MPTP and lactacystin. MAO-IN-M30 dihydrochloride functions as a click chemistry reagent due to its alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) for various research applications. -
Monoamine Oxidase Inhibitor
Modaline sulfate is a potent monoamine oxidase (MAO) inhibitor that plays a significant role in the modulation of neurotransmitter levels. It has been primarily investigated for its efficacy in treating depression by preventing the breakdown of serotonin, norepinephrine, and dopamine. This compound serves as a valuable tool in research focused on mood disorders and the neurochemical pathways involved in depression. -
hMAO-B Inhibitor
Ethyl 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate is a selective inhibitor of human monoamine oxidase B (hMAO-B), demonstrating an IC50 of 45.52 μM. This compound is valuable in research focused on neurodegenerative diseases, as it modulates monoamine metabolism and has implications for the treatment of conditions such as Parkinson's disease. Its potent inhibition of hMAO-B makes it a useful tool for investigating the role of this enzyme in various biological processes. -
MAO-B Inhibitor
Selegiline is a potent, selective, and irreversible inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 51 nM and demonstrating 450-fold selectivity over MAO-A (IC50 = 23 μM). This compound is primarily researched for its neuroprotective effects and potential therapeutic applications in Parkinson's disease, Alzheimer's disease, and major depressive disorder. Its ability to influence dopaminergic pathways makes it a valuable reagent in studies related to neurodegeneration and mood disorders. -
MAO Inhibitor
Hydroxylamine (50% w/w in water) is a selective inhibitor of monoamine oxidase (MAO), making it valuable in research applications focused on platelet aggregation inhibition. As an important intermediate in the nitrogen cycle, it plays a role in the metabolism of aerobic ammonium-oxidizing microorganisms, including ammonium oxidizing bacteria (AOB) and complete ammonium oxidizing bacteria (comammox). Hydroxylamine also influences nitrous oxide (NO) and nitrogen gas (N2O) emissions by modulating the activity of nitrite-oxidizing bacteria (NOB). -
MAO-A Inhibitor
MAO-A Inhibitor 3 is a selective inhibitor of monoamine oxidase A (MAO-A), displaying an IC50 of greater than 100 μM. This compound is utilized in the investigation of neurological disorders, providing insights into the role of MAO-A in the metabolism of neurotransmitters and its implications in various neuropsychiatric conditions. Its application may contribute to the understanding of the biochemical pathways involved in mood regulation and depression. -
MAO-A Inhibitor
Befloxatone is a selective and reversible inhibitor of Monoamine Oxidase A (MAO-A), exhibiting an IC50 of 4 nM. By inhibiting MAO-A, Befloxatone effectively elevates the tissue levels of monoamines, including striatal dopamine and cortical norepinephrine. This compound is primarily investigated for its potential antidepressant effects, making it a valuable reagent in research related to mood disorders and neuropharmacology.
